Your browser doesn't support javascript.
loading
A new classification of cardio-oncology syndromes.
de Boer, Rudolf A; Aboumsallem, Joseph Pierre; Bracun, Valentina; Leedy, Douglas; Cheng, Richard; Patel, Sahishnu; Rayan, David; Zaharova, Svetlana; Rymer, Jennifer; Kwan, Jennifer M; Levenson, Joshua; Ronco, Claudio; Thavendiranathan, Paaladinesh; Brown, Sherry-Ann.
Afiliación
  • de Boer RA; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Aboumsallem JP; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Bracun V; Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
  • Leedy D; Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Cheng R; Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.
  • Patel S; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Rayan D; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Zaharova S; Cardio-Oncology Program, Division of Cardiovascular Medicine, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI, 53226, USA.
  • Rymer J; Duke University, Durham, NC, USA.
  • Kwan JM; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Levenson J; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Ronco C; Department of Medicine, University of Padova, Padova, Italy.
  • Thavendiranathan P; International Renal Research Institute of Vicenza, Vicenza, Italy.
  • Brown SA; Department of Nephrology, San Bortolo Hospital, Vicenza, Italy.
Cardiooncology ; 7(1): 24, 2021 Jun 21.
Article en En | MEDLINE | ID: mdl-34154667
Increasing evidence suggests a multifaceted relationship exists between cancer and cardiovascular disease (CVD). Here, we introduce a 5-tier classification system to categorize cardio-oncology syndromes (COS) that represent the aspects of the relationship between cancer and CVD. COS Type I is characterized by mechanisms whereby the abrupt onset or progression of cancer can lead to cardiovascular dysfunction. COS Type II includes the mechanisms by which cancer therapies can result in acute or chronic CVD. COS Type III is characterized by the pro-oncogenic environment created by the release of cardiokines and high oxidative stress in patients with cardiovascular dysfunction. COS Type IV is comprised of CVD therapies and diagnostic procedures which have been associated with promoting or unmasking cancer. COS Type V is characterized by factors causing systemic and genetic predisposition to both CVD and cancer. The development of this framework may allow for an increased facilitation of cancer care while optimizing cardiovascular health through focused treatment targeting the COS type.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cardiooncology Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cardiooncology Año: 2021 Tipo del documento: Article